Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2014
|
| In: |
Investigational new drugs
Year: 2014, Jahrgang: 32, Heft: 1, Pages: 123-134 |
| ISSN: | 1573-0646 |
| DOI: | 10.1007/s10637-013-9958-3 |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s10637-013-9958-3 Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1007/s10637-013-9958-3 
|
| Verfasserangaben: | Eberhardt, Wilfried E. E. ...Thomas, Michael ... |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1484636678 | ||
| 003 | DE-627 | ||
| 005 | 20241002131821.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 140918s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10637-013-9958-3 |2 doi | |
| 035 | |a (DE-627)1484636678 | ||
| 035 | |a (DE-576)414636678 | ||
| 035 | |a (DE-599)BSZ414636678 | ||
| 035 | |a (OCoLC)1340649386 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 245 | 0 | 0 | |a Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer |c Eberhardt, Wilfried E. E. ...Thomas, Michael ... |
| 264 | 1 | |c 2014 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.09.2014 | ||
| 700 | 1 | |a Eberhardt, Wilfried E. E. |0 (DE-588)1058450573 |0 (DE-627)796897654 |0 (DE-576)414636554 |4 oth | |
| 700 | 1 | |a Thomas, Michael |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 oth | |
| 773 | 0 | 8 | |i In |t Investigational new drugs |d Dordrecht [u.a.] : Springer Science + Business Media B.V, 1983 |g 32(2014), 1, Seite 123-134 |h Online-Ressource |w (DE-627)320481492 |w (DE-600)2009846-7 |w (DE-576)121191028 |x 1573-0646 |7 nnas |a Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer |
| 773 | 1 | 8 | |g volume:32 |g year:2014 |g number:1 |g pages:123-134 |g extent:12 |a Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s10637-013-9958-3 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10637-013-9958-3 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20140918 | ||
| 993 | |a Article | ||
| 994 | |a 2014 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 5 | ||
| 999 | |a KXP-PPN1484636678 |e 2815768720 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 18.09.2014"],"language":["eng"],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"320481492","note":["Gesehen am 17.10.05","Fortsetzung der Druck-Ausgabe"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"pubHistory":["1.1983 -"],"part":{"pages":"123-134","year":"2014","text":"32(2014), 1, Seite 123-134","extent":"12","volume":"32","issue":"1"},"id":{"zdb":["2009846-7"],"eki":["320481492"],"issn":["1573-0646"]},"origin":[{"dateIssuedDisp":"1983-","publisher":"Springer Science + Business Media B.V ; Kluwer","publisherPlace":"Dordrecht [u.a.] ; Dordrecht [u.a.]","dateIssuedKey":"1983"}],"disp":"Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancerInvestigational new drugs","title":[{"title_sort":"Investigational new drugs","title":"Investigational new drugs","subtitle":"an interdisciplinary journal for clinicians and scientists"}]}],"recId":"1484636678","physDesc":[{"extent":"12 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Eberhardt, Wilfried E. E. ...Thomas, Michael ..."]},"title":[{"title":"Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer","title_sort":"Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer"}],"origin":[{"dateIssuedDisp":"2014","dateIssuedKey":"2014"}],"person":[{"role":"oth","display":"Eberhardt, Wilfried E. E.","family":"Eberhardt","given":"Wilfried E. E."},{"given":"Michael","family":"Thomas","display":"Thomas, Michael","role":"oth"}],"id":{"doi":["10.1007/s10637-013-9958-3"],"eki":["1484636678"]}} | ||
| SRT | |a FEASIBILIT2014 | ||